Previous 10 | Next 10 |
MAA submission is supported by positive results from MAESTRO-NASH, the only Phase 3 trial in NASH to achieve fibrosis reduction and NASH resolution primary endpoints Resmetirom new drug application is currently under review with the FDA with a PDUFA date of March 14, 2024 CONSHO...
2024-03-05 06:03:00 ET Following the biotech reporting its earnings on Feb. 28, JMP Securities' analyst Jonathan Wolleben reiterated his opinion on Feb. 29 that Madrigal Pharmaceuticals (NASDAQ: MDGL) stock (priced at $247 a share) will rise by around 40% over the next 12 to 18 mont...
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer. M...
Announced appointment of Mardi C. Dier as Chief Financial Officer Anticipates resmetirom to become the first medicine approved for NASH; PDUFA date March 14, 2024 Reports year-end 2023 cash, cash equivalents and marketable securities of $634 million CONSHOHOCKEN, Pa., Fe...
2024-02-23 05:43:00 ET Over the past year, shares of mid-cap biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) have taken a beating, down by 25%. However, things could change in 2024. The drugmaker is awaiting a major catalyst that could send its stock price soaring. What's more, Wall...
2024-02-14 18:39:12 ET More on Madrigal, NovaGold, etc. Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) NovaGold: No Feasiblity Refresh Planned This Year Read the f...
2024-02-12 15:06:51 ET More on CymaBay, Gilead, etc. Gilead Sciences: Cheap For A Reason Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead to acquire CymaBay for $32.50/sh...
2024-02-10 04:43:54 ET Summary On Tuesday, Feb 6, when Eli Lilly announced their Q4 2023 report, the stocks of NASH (nonalcoholic steatohepatitis) drug developers, including Madrigal Pharmaceuticals, all came under selling pressure. It seems that the reason for the sell-off was th...
Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial Detailed analyses reinforce the safety profile of resmetirom Resmetirom has the potential to become the first and only medicine approv...
2024-02-08 02:25:34 ET Summary Eli Lilly's tirzepatide shows potential in treating MASH, challenging Madrigal Pharmaceuticals' resmetirom. Despite Madrigal's solid financials, Eli Lilly's advancements hint at market recalibration, adversely affecting Madrigal's valuation and futur...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...